Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
734 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01515189 | Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | completed | Phase 3 | 831 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 31, 2019 | clinicaltrials |
| NCT01039376 | Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy(PROLONG) | terminated | Phase 3 | 480 | Novartis PharmaceuticalsINDUSTRY | 25 | Jul 30, 2019 |
| clinicaltrials |
| NCT01667419 | A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma(BRIM8) | completed | Phase 3 | 498 | Hoffmann-La RocheINDUSTRY | 29 | Jul 23, 2019 | clinicaltrials |
| NCT02292446 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | completed | Phase 3 | 161 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 18, 2019 | clinicaltrials |
| NCT01178281 | Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence(RESUME) | completed | Phase 3 | 267 | CelgeneINDUSTRY | 16 | Jul 17, 2019 | clinicaltrials |
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) | completed | Phase 3 | 125 | Alexion Pharmaceuticals, Inc.INDUSTRY | 21 | Jul 16, 2019 | clinicaltrials |
| NCT01310894 | Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.(PCM301) | completed | Phase 3 | 413 | Steba Biotech S.A.OTHER | 10 | Jul 11, 2019 | clinicaltrials |
| NCT00748189 | Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia(COMPLEMENT 1) | terminated | Phase 3 | 447 | Novartis PharmaceuticalsINDUSTRY | 17 | Jun 25, 2019 | clinicaltrials |
| NCT01308567 | Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer(FIRSTANA) | completed | Phase 3 | 1,168 | SanofiINDUSTRY | 25 | Jun 5, 2019 | clinicaltrials |
| NCT00820222 | Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | completed | Phase 3 | 540 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 2, 2019 | clinicaltrials |
| NCT02472145 | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | completed | Phase 2 / Phase 3 | 326 | Janssen Research & Development, LLCINDUSTRY | 14 | Mar 19, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT00646854 | Alemtuzumab and CHOP in T-cell Lymphoma(ACT-1) | completed | Phase 3 | 136 | Aarhus University HospitalOTHER | 11 | Mar 1, 2019 | clinicaltrials |
| NCT01633060 | A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi(BELLE-3) | terminated | Phase 3 | 432 | Novartis PharmaceuticalsINDUSTRY | 22 | Jan 30, 2019 | clinicaltrials |
| NCT02256228 | Intra-Peritoneal Local Anaesthesia After Cytoreductive Surgery(IPLA) | completed | Phase 3 | 40 | Göteborg UniversityOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00678392 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | completed | Phase 3 | 723 | PfizerINDUSTRY | 22 | Jan 9, 2019 | clinicaltrials |
| NCT01564784 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | completed | Phase 3 | 326 | PfizerINDUSTRY | 20 | Jan 9, 2019 | clinicaltrials |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite) | terminated | Phase 3 | 295 | Gilead SciencesINDUSTRY | 19 | Nov 16, 2018 | clinicaltrials |
| NCT01732926 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Bridalveil) | terminated | Phase 3 | 475 | Gilead SciencesINDUSTRY | 15 | Nov 16, 2018 | clinicaltrials |
| NCT01313689 | Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | completed | Phase 3 | 122 | Novartis PharmaceuticalsINDUSTRY | 17 | Nov 8, 2018 | clinicaltrials |
| NCT02942537 | Study of Volume Reduction of Uterine Fibroids After Embolization or Microwave Treatment(MYOMIC1) | unknown | Phase 2 / Phase 3 | 36 | Karolinska InstitutetOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01305655 | Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL(NOPHOCPG2) | completed | Phase 3 | 47 | Nordic Society for Pediatric Hematology and OncologyOTHER | 5 | Sep 28, 2018 | clinicaltrials |
| NCT00375674 | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer(S-TRAC) | completed | Phase 3 | 674 | PfizerINDUSTRY | 22 | Sep 21, 2018 | clinicaltrials |
| NCT00984282 | Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | completed | Phase 3 | 417 | BayerINDUSTRY | 18 | Sep 13, 2018 | clinicaltrials |
| NCT00332202 | PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | completed | Phase 3 | 758 | Eli Lilly and CompanyINDUSTRY | 25 | Sep 10, 2018 | clinicaltrials |
| NCT00578227 | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects | completed | Phase 3 | 814 | GlaxoSmithKlineINDUSTRY | 4 | Aug 17, 2018 | clinicaltrials |
| NCT00652938 | Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects | completed | Phase 3 | 744 | GlaxoSmithKlineINDUSTRY | 2 | Aug 17, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT00333788 | Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease(Welcome2) | completed | Phase 3 | 233 | UCB PharmaINDUSTRY | 12 | Aug 7, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT01006252 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma(SUMMIT-1) | terminated | Phase 3 | 336 | Eli Lilly and CompanyINDUSTRY | 18 | Jul 17, 2018 | clinicaltrials |
| NCT01767467 | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | completed | Phase 3 | 568 | GlaxoSmithKlineINDUSTRY | 21 | Jun 6, 2018 | clinicaltrials |
| NCT01571284 | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | completed | Phase 3 | 781 | SanofiINDUSTRY | 23 | Apr 17, 2018 | clinicaltrials |
| NCT01245062 | GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | completed | Phase 3 | 322 | GlaxoSmithKlineINDUSTRY | 19 | Apr 5, 2018 | clinicaltrials |
| NCT00988208 | Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer(Mainsail) | completed | Phase 3 | 1,059 | CelgeneINDUSTRY | 21 | Apr 4, 2018 | clinicaltrials |
| NCT02907385 | Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing | unknown | Phase 3 | 736 | LifeBond Ltd.INDUSTRY | 7 | Mar 30, 2018 | clinicaltrials |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100(COMET-1) | completed | Phase 3 | 1,028 | ExelixisINDUSTRY | 14 | Mar 14, 2018 | clinicaltrials |
| NCT01345682 | LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 483 | Boehringer IngelheimINDUSTRY | 19 | Feb 15, 2018 | clinicaltrials |
| NCT02119663 | A Study of Ruxolitinib in Pancreatic Cancer Patients | terminated | Phase 3 | 86 | Incyte CorporationINDUSTRY | 14 | Feb 13, 2018 | clinicaltrials |
| NCT00950300 | A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer | completed | Phase 3 | 596 | Hoffmann-La RocheINDUSTRY | 26 | Jan 23, 2018 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT01646021 | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | completed | Phase 3 | 280 | Janssen Research & Development, LLCINDUSTRY | 21 | Jan 19, 2018 | clinicaltrials |
| NCT00036647 | OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 3 | 731 | OSI PharmaceuticalsINDUSTRY | 17 | Jan 10, 2018 | clinicaltrials |
| NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | unknown | Phase 3 | 870 | Prof. Dr. M. Dreyling (co-chairman)OTHER | 5 | Dec 19, 2017 | clinicaltrials |
| NCT01307397 | A Study of Vemurafenib in Participants With Metastatic Melanoma | completed | Phase 3 | 3,219 | Hoffmann-La RocheINDUSTRY | 44 | Dec 18, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials